Literature DB >> 1471552

Long-term Antabuse treatment: tolerance and reasons for withdrawal.

C Børup1, A Kaiser, E Jensen.   

Abstract

We studied 210 alcoholics, who were re-admitted to a disulfiram treatment programme after having voluntarily discontinued disulfiram therapy, primarily to ascertain whether illness, hospitalization, or serious adverse effects were the cause of the withdrawal. A simple 9-item questionnaire was used. About 70% of the patients gave either "a wish to drink again" or "no need for further treatment" as the reason. Withdrawal in the remaining patients was in no case related to adverse effects of disulfiram. The low incidence of adverse effects was confirmed in another group comprising 93 patients treated under supervision with disulfiram 600-800 mg twice a week for at least a year (i.e. total dose at least 70 g disulfiram). They were monitored by standard laboratory blood and urine tests. There were no clinically significant changes in the measures used. Indeed, many of the patients improved during the year of abstinence. These two studies add weight to the evidence that disulfiram is not a drug with a high incidence of adverse effects.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1471552     DOI: 10.1111/j.1600-0447.1992.tb03315.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand Suppl        ISSN: 0065-1591


  9 in total

1.  Experimental determination and calculations of redox potential descriptors of compounds directed against retroviral zinc fingers: Implications for rational drug design.

Authors:  I A Topol; C McGrath; E Chertova; C Dasenbrock; W R Lacourse; M A Eissenstat; S K Burt; L E Henderson; J R Casas-Finet
Journal:  Protein Sci       Date:  2001-07       Impact factor: 6.725

Review 2.  Safety issues concerning the use of disulfiram in treating alcohol dependence.

Authors:  J Chick
Journal:  Drug Saf       Date:  1999-05       Impact factor: 5.606

3.  Adverse effects of disulfiram and patient compliance.

Authors:  T N Srinivasan; T R Suresh; J Vasantha
Journal:  Indian J Psychiatry       Date:  1996-01       Impact factor: 1.759

4.  CURRENT STATUS OF DISULFIRAM THERAPY.

Authors:  P K Chakraborty; H Singh; K J Divinakumar
Journal:  Med J Armed Forces India       Date:  2011-07-21

5.  Status of disulfiram in present day alcoholic deaddiction therapy.

Authors:  Princy Louis Palatty; Elroy Saldanha
Journal:  Indian J Psychiatry       Date:  2011-01       Impact factor: 1.759

6.  Long-acting Preparations in Substance Abuse Management: A Review and Update.

Authors:  Aditya Hegde; Shubh Mohan Singh; Siddharth Sarkar
Journal:  Indian J Psychol Med       Date:  2013-01

7.  Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent.

Authors:  Mohamed Wehbe; Malathi Anantha; Minghan Shi; Ada Wai-Yin Leung; Wieslawa H Dragowska; Léon Sanche; Marcel B Bally
Journal:  Int J Nanomedicine       Date:  2017-05-31

8.  Disulfiram Acts as a Potent Radio-Chemo Sensitizer in Head and Neck Squamous Cell Carcinoma Cell Lines and Transplanted Xenografts.

Authors:  Wenhao Yao; Xu Qian; Sebastian Ochsenreither; Ferrone Soldano; Albert B DeLeo; Holger Sudhoff; Felix Oppel; Andreas Kuppig; Konrad Klinghammer; Andreas M Kaufmann; Andreas E Albers
Journal:  Cells       Date:  2021-02-28       Impact factor: 7.666

9.  Drug Repurposing of the Alcohol Abuse Medication Disulfiram as an Anti-Parasitic Agent.

Authors:  Debbie-Ann Shirley; Ishrya Sharma; Cirle A Warren; Shannon Moonah
Journal:  Front Cell Infect Microbiol       Date:  2021-03-11       Impact factor: 6.073

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.